Crescent Biopharma, Inc. (CBIO)
NASDAQ: CBIO · Real-Time Price · USD
13.07
+0.08 (0.62%)
At close: Dec 5, 2025, 4:00 PM EST
12.60
-0.47 (-3.60%)
After-hours: Dec 5, 2025, 7:42 PM EST
Crescent Biopharma Statistics
Total Valuation
CBIO has a market cap or net worth of $255.51 million. The enterprise value is $258.23 million.
| Market Cap | 255.51M |
| Enterprise Value | 258.23M |
Important Dates
The last earnings date was Thursday, November 6, 2025, before market open.
| Earnings Date | Nov 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CBIO has 19.55 million shares outstanding.
| Current Share Class | 13.89M |
| Shares Outstanding | 19.55M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +339.38% |
| Owned by Insiders (%) | 7.89% |
| Owned by Institutions (%) | 36.70% |
| Float | 6.07M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.62
| Current Ratio | 3.62 |
| Quick Ratio | 3.62 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -20.18 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -264.45% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$11.91M |
| Employee Count | 6 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 12.67 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 47.66 |
| Average Volume (20 Days) | 182,331 |
Short Selling Information
The latest short interest is 580,842, so 2.97% of the outstanding shares have been sold short.
| Short Interest | 580,842 |
| Short Previous Month | 577,578 |
| Short % of Shares Out | 2.97% |
| Short % of Float | 9.56% |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -68.76M |
| Pretax Income | -71.47M |
| Net Income | -71.47M |
| EBITDA | n/a |
| EBIT | -68.76M |
| Earnings Per Share (EPS) | -$13.45 |
Balance Sheet
The company has $34.77 million in cash and $37.48 million in debt, giving a net cash position of -$2.72 million or -$0.14 per share.
| Cash & Cash Equivalents | 34.77M |
| Total Debt | 37.48M |
| Net Cash | -2.72M |
| Net Cash Per Share | -$0.14 |
| Equity (Book Value) | -11.48M |
| Book Value Per Share | -2.20 |
| Working Capital | 25.19M |
Cash Flow
| Operating Cash Flow | -25.08M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CBIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -27.97% |
| FCF Yield | n/a |
Analyst Forecast
The average price target for CBIO is $25.60, which is 95.87% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $25.60 |
| Price Target Difference | 95.87% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |